Assetmark Inc. Grows Position in Natera, Inc. (NASDAQ:NTRA)

Assetmark Inc. boosted its holdings in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 28.6% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,340 shares of the medical research company's stock after acquiring an additional 3,186 shares during the period. Assetmark Inc.'s holdings in Natera were worth $2,028,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the business. LRI Investments LLC bought a new stake in Natera during the 4th quarter valued at about $29,000. Rakuten Securities Inc. grew its stake in shares of Natera by 117.8% in the first quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company's stock worth $31,000 after acquiring an additional 119 shares during the period. ORG Partners LLC bought a new stake in shares of Natera in the first quarter worth approximately $32,000. ANTIPODES PARTNERS Ltd bought a new stake in shares of Natera in the first quarter worth approximately $40,000. Finally, Covestor Ltd grew its stake in shares of Natera by 42.7% in the fourth quarter. Covestor Ltd now owns 531 shares of the medical research company's stock worth $84,000 after acquiring an additional 159 shares during the period. 99.90% of the stock is owned by hedge funds and other institutional investors.

Natera Trading Up 0.7%

NTRA traded up $0.92 during trading hours on Friday, hitting $134.58. The company's stock had a trading volume of 1,165,817 shares, compared to its average volume of 1,202,365. The business's 50-day moving average price is $157.16 and its 200-day moving average price is $155.88. Natera, Inc. has a 12 month low of $92.14 and a 12 month high of $183.00. The stock has a market cap of $18.38 billion, a price-to-earnings ratio of -91.55 and a beta of 1.76.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The medical research company reported ($0.50) earnings per share for the quarter, topping the consensus estimate of ($0.59) by $0.09. Natera had a negative net margin of 10.36% and a negative return on equity of 18.29%. The company had revenue of $501.83 million for the quarter, compared to analysts' expectations of $446.68 million. During the same quarter in the previous year, the business posted ($0.56) earnings per share. Natera's quarterly revenue was up 36.5% on a year-over-year basis. On average, analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current year.

Wall Street Analysts Forecast Growth

NTRA has been the subject of a number of research analyst reports. Piper Sandler lifted their price target on shares of Natera from $205.00 to $210.00 and gave the stock an "overweight" rating in a research note on Thursday, May 15th. Barclays lifted their price target on shares of Natera from $160.00 to $190.00 and gave the stock an "overweight" rating in a research note on Friday, May 9th. Wall Street Zen lowered shares of Natera from a "hold" rating to a "sell" rating in a research note on Saturday, May 17th. Evercore ISI assumed coverage on shares of Natera in a research note on Monday. They issued an "outperform" rating and a $170.00 price target for the company. Finally, UBS Group raised their price objective on shares of Natera from $211.00 to $218.00 and gave the stock a "buy" rating in a report on Friday, May 9th. One analyst has rated the stock with a sell rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $183.76.

Insider Activity

In other Natera news, Director Gail Boxer Marcus sold 4,299 shares of the business's stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $167.36, for a total transaction of $719,480.64. Following the transaction, the director owned 8,118 shares in the company, valued at $1,358,628.48. The trade was a 34.62% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Steven Leonard Chapman sold 6,111 shares of the business's stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $157.10, for a total transaction of $960,038.10. Following the transaction, the chief executive officer owned 179,071 shares in the company, valued at $28,132,054.10. This trade represents a 3.30% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 48,936 shares of company stock worth $7,483,846. 7.60% of the stock is currently owned by insiders.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.